UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 1 – Exit Filing)*

 

Theravance Biopharma, Inc.
(Name of Issuer)
 
Ordinary Shares
(Title of Class of Securities)

 

G8807B106
(CUSIP Number)
 
May 10, 2024
(Date of Event Which Requires Filing of This Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  ¨ Rule 13d-1(b)
  x Rule 13d-1(c)
  ¨ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

  
 

 

CUSIP No. G8807B106
1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

ODRE 2005 SL

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a)¨

(b)¨

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

Spain

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

 5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.0%

12

TYPE OF REPORTING PERSON (see instructions)

OO

 

  
 

 

CUSIP No. G8807B106
1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

LUIS GÓMEZ LAGUNA

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a)¨

(b)¨

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

Spain

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

 5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.0%

12

TYPE OF REPORTING PERSON (see instructions)

IN

 

Item 1(a). Name of Issuer:
   
  Theravance Biopharma, Inc.
   
Item 1(b). Address of Issuer’s Principal Executive Offices:
   
 

901 Gateway Boulevard

South San Francisco, CA 94080

   
Item 2(a). Name of Person Filing:
   
 

This Schedule 13G is filed jointly by:

 

(1) ODRE 2005 SL

 

(2) Luis Gómez Laguna

 

The agreement between the reporting persons relating to the joint filing of this Schedule 13G is attached hereto as Exhibit 1.

   
Item 2(b). Address of Principal Business Office or, if none, Residence:
   
  Pineta, 18B, Polígono Valdeconsejo, Nave 5, CP50410, Cuarte de Huerva (Zaragoza), Spain

 

  
 

 

Item 2(c). Citizenship:
   
  ODRE 2005 SL is sociedad limitada organized under the laws of Spain.
Mr. Gómez Laguna is a citizen of Spain.
   
Item 2(d). Title of Class of Securities:
   
  Ordinary Shares
   
Item 2(e). CUSIP Number: G8807B106

 

Item 3. Not applicable  
     
Item 4.

Ownership.

 

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

   
  (a) Amount Beneficially Owned: 0
       
  (b) Percent of Class: 0.0%
       
  (c) Number of shares as to which such person has:
     
    (i) sole power to vote or to direct the vote: 0
    (ii) shared power to vote or to direct the vote: 0
    (iii) sole power to dispose or to direct the disposition of: 0
    (iv) shared power to dispose or to direct the disposition of: 0

 

Item 5. Ownership of Five Percent or Less of a Class.
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

 

  
 

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.
   
  No.
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
   
  Not applicable.
   
Item 8. Identification and Classification of Members of the Group.
   
  Not applicable.
   
Item 9. Notice of Dissolution of Group.
   
  Not applicable.
   
Item 10. Certification.
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

Exhibits:1 Joint Filing Agreement, dated as of June 11, 2024, by and between ODRE 2005 SL and Luis Gómez Laguna

 

  
 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: June 11, 2024

 

ODRE 2005 SL  
   
By: /s/ Luis Gómez Laguna  
  Name: Luis Gómez Laguna  
  Title: Director  
   
Luis Gómez Laguna  
   
By: /s/ Luis Gómez Laguna  
  Individually  

 

  
 

 

EXHIBIT 1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13(d)-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other of the attached statement on Schedule 13G and to all amendments to such statement.

 

Dated: June 11, 2024

 

ODRE 2005 SL  
   
By: /s/ Luis Gómez Laguna  
  Name: Luis Gómez Laguna  
  Title: Director  
   
Luis Gómez Laguna  
   
By: /s/ Luis Gómez Laguna  
  Individually  

 

 

 

 

 

 

Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Theravance Biopharma Charts.
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Theravance Biopharma Charts.